Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161757 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
A Phase 3 study of Uncontrolled Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,207
- Enrollment target
- 20
- Study locations
NCT02161757 is a Phase 3 study of Uncontrolled Asthma that has completed, run by AstraZeneca. The registered enrollment target is 1,207 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT02161757, a Phase 3 study of Uncontrolled Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,207 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab
Study Locations (20)
California
- Research Site - Arcadia
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Poway
- Research Site - San Jose
- Research Site - Tustin
- Research Site - Wildomar
Florida
- Research Site - Clearwater
- Research Site - Coral Gables
- Research Site - Cutler Bay
- Research Site - Fort Lauderdale
- Research Site - Hialeah
- Research Site - Hialeah
Colorado
- Research Site - Colorado Springs
- Research Site - Denver
- Research Site - Denver
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Phoenix
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,207 participants |
| Start Date | 2014-06-13 |
| Est. Completion | 2017-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161757
The ClinicalTrials.gov registry entry for NCT02161757 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uncontrolled Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02161757 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02161757 about?
NCT02161757 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma". A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
What is the current status of trial NCT02161757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,207 participants. The study started on 2014-06-13. Estimated completion is 2017-07-18.
What conditions does trial NCT02161757 study?
This clinical trial studies the following conditions: Uncontrolled Asthma.
What interventions are being tested in trial NCT02161757?
The interventions under investigation include: Placebo (OTHER), Tralokinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02161757?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02161757 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.